Immunic, Inc. Common Stock
IMUX Real Time Price USDRecent trades of IMUX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by IMUX's directors and management
Government lobbying spending instances
-
$10,000 Jan 20, 2022 Issue: None
-
$20,000 Jan 20, 2022 Issue: None
-
$10,000 Oct 20, 2021 Issue: None
-
$20,000 Oct 20, 2021 Issue: None
-
$20,000 Jul 20, 2021 Issue: None
-
$20,000 Apr 20, 2021 Issue: None
-
$20,000 Jan 20, 2021 Issue: None
-
$10,000 Jul 20, 2020 Issue: Health Issues Medical/Disease Research/Clinical Labs Science/Technology
-
$10,000 Jul 17, 2020 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents Jul. 16, 2024
-
Patent Title: Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases Jan. 23, 2024
-
Patent Title: Treatment of multiple sclerosis comprising dhodh inhibitors Jan. 23, 2024
-
Patent Title: Vidofludimus for use in the treatment or prevention of viral diseases Jul. 05, 2022
-
Patent Title: Il-17 and ifn-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation Apr. 05, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of IMUX in WallStreetBets Daily Discussion
Recent insights relating to IMUX
Recent picks made for IMUX stock on CNBC
ETFs with the largest estimated holdings in IMUX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IMUX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.